ClinicalTrials.gg
CompletedNCT00396318TROPICS 2Updated Apr 27, 2011Results posted

A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters

A Phase 3 interventional study of tenecteplase in Dysfunctional Central Venous Access Catheters, sponsored by Genentech, Inc.. Completed. Per ClinicalTrials.gov, last updated 2011-04-27.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
251
Allocation
Non-randomized
Sex
All
01

Study summary

This was a Phase III, open-label, single-arm study that was conducted at 43 centers in the United States and Canada. 251 adult and pediatric patients with dysfunctional central venous catheters (CVCs) were enrolled in the study and treated with one or two doses of tenecteplase.

02

Conditions studied

  • Dysfunctional Central Venous Access Catheters

Keywords

  • TNKase
  • CVA
  • CVAD
  • Central venous access catheter
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically stable, in the opinion of the investigator
  • CVC occlusion
  • Able to have fluids infused at the volume necessary to instill study drug into the CVC

Exclusion criteria

Exclusion Criteria:

  • Able to have 3 mL of blood (patients weighing ≥ 10 kg) or 1 mL of blood (patients weighing \< 10 kg) withdrawn from the selected CVC following patient repositioning
  • Selected study CVC inserted \< 2 days prior to treatment
  • Selected study CVC implanted specifically for hemodialysis (HD) or internally coated with any therapeutic agent
  • Use of a power injector on the selected study CVC during study drug treatment
  • Evidence of mechanical, non-thrombotic occlusion of the selected study CVC (e.g., kink in the catheter or suture constricting the catheter)
  • Previously treated in this study or any tenecteplase catheter clearance trial
  • Use of any drug or therapy within 28 days prior to treatment
  • Use of a fibrinolytic agent (e.g., alteplase, tenecteplase, reteplase, or urokinase) within 24 hours prior to treatment
  • Known to be pregnant or breastfeeding at screening
  • Known bacteremia or known or suspected infection in the CVC catheter
  • Known history of intracranial hemorrhage (within the previous 3 years), intracranial aneurysm, or arteriovenous malformation
  • Use of heparin (unfractionated or low molecular weight) or any other anticoagulants within 24 hours prior to treatment, except heparin used for prophylaxis or intermittent or low-dose, continuous infusion of heparin to maintain catheter or vessel patency
  • Subjects treated with warfarin only: (INR) ≥ 3.0 within 7 days prior to Visit 1, or a target INR range that allows for an INR ≥ 3.0
  • Initiation of or increase in dose of Plavix® (clopidogrel bisulfate) within 7 days prior to treatment
  • At high risk for bleeding events or embolic complications (i.e., recent pulmonary embolus, deep vein thrombosis, endarterectomy, or right-to-left shunt) in the opinion of the investigator, or with known condition for which bleeding constitutes a significant hazard
  • Known to tenecteplase or any component of the formulation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    Tenecteplase

    Drug: tenecteplase

Interventions

  • 2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of tenecteplase (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of tenecteplase equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Who Had Cumulative Restoration Rates of Central Venous Catheter (CVC) Function Following a Single Administration of Tenecteplase

    Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

    Time frame: 120 minutes after first dose

Secondary outcomes

  1. Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Single Administration of Tenecteplase

    Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

    Time frame: 15 minutes after first dose

  2. Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Single Administration of Tenecteplase

    Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

    Time frame: 30 minutes after first dose

  3. Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase

    Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

    Time frame: 15 minutes after second dose

  4. Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase

    Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

    Time frame: 30 minutes after second dose

  5. Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase

    Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

    Time frame: 120 minutes after second dose

  6. Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following Administration of One or Two Doses of Tenecteplase

    Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

    Time frame: Up to 120 minutes post-treatment (Dose 1 or Dose 2)

  7. Percentage of Patients Who Had Cumulative Restoration Rates Restoration Rates of CVC Function at Any Time During the Study and Who Maintained Catheter Patency the Next Time the Catheter Was Assessed, up to 7 Days Following the Last Dose of Tenecteplase

    Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

    Time frame: Up to 7 days post-treatment

07

Results

Posted Apr 27, 2011

Participant flow

At Least One Dose of Tenecteplase (MITT)
Participant flow — At Least One Dose of Tenecteplase (MITT)
MilestoneTenecteplase
Started246
Completed241
Not completed5
Withdrew: Subject withdrew consent5
48- to 96-Hour Follow-Up Period
Participant flow — 48- to 96-Hour Follow-Up Period
MilestoneTenecteplase
Started246
Completed241
Not completed5
7-Day Post-Treatment Contact
Participant flow — 7-Day Post-Treatment Contact
MilestoneTenecteplase
Started241
Completed240
Not completed1

Outcome measures

PrimaryPercentage of Patients Who Had Cumulative Restoration Rates of Central Venous Catheter (CVC) Function Following a Single Administration of Tenecteplase

Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

Time frame:
120 minutes after first dose
Reported as:
Number · percentage of participants
Percentage of Patients Who Had Cumulative Restoration Rates of Central Venous Catheter (CVC) Function Following a Single Administration of Tenecteplase
percentage of participantsTenecteplase
Percentage of Patients Who Had Cumulative Restoration Rates of Central Venous Catheter (CVC) Function Following a Single Administration of Tenecteplase72.0 (66.3 to 77.6)
SecondaryPercentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Single Administration of Tenecteplase

Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

Time frame:
15 minutes after first dose
Reported as:
Number · percentage of participants
Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Single Administration of Tenecteplase
percentage of participantsTenecteplase
Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Single Administration of Tenecteplase29.3 (23.6 to 35.0)
SecondaryPercentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Single Administration of Tenecteplase

Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

Time frame:
30 minutes after first dose
Reported as:
Number · percentage of participants
Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Single Administration of Tenecteplase
percentage of participantsTenecteplase
Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Single Administration of Tenecteplase53.3 (47.0 to 59.5)
SecondaryPercentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase

Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

Time frame:
15 minutes after second dose
Reported as:
Number · percentage of participants
Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase
percentage of participantsTenecteplase
Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase76.4 (71.1 to 81.7)
SecondaryPercentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase

Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

Time frame:
30 minutes after second dose
Reported as:
Number · percentage of participants
Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase
percentage of participantsTenecteplase
Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase78.5 (73.3 to 83.6)
SecondaryPercentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase

Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

Time frame:
120 minutes after second dose
Reported as:
Number · percentage of participants
Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase
percentage of participantsTenecteplase
Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following a Second Administration of Tenecteplase81.3 (76.4 to 86.2)
SecondaryPercentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following Administration of One or Two Doses of Tenecteplase

Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

Time frame:
Up to 120 minutes post-treatment (Dose 1 or Dose 2)
Reported as:
Number · percentage of participants
Percentage of Patients Who Had Cumulative Restoration Rates of CVC Function Following Administration of One or Two Doses of Tenecteplase
percentage of participantsTenecteplase
Through first tenecteplase instillation72.0 (66.3 to 77.6)
Through second tenecteplase instillation81.3 (76.4 to 86.2)
SecondaryPercentage of Patients Who Had Cumulative Restoration Rates Restoration Rates of CVC Function at Any Time During the Study and Who Maintained Catheter Patency the Next Time the Catheter Was Assessed, up to 7 Days Following the Last Dose of Tenecteplase

Restoration of CVC function was defined as the successful withdrawal of at least 3 mL of blood or fluid and infusion of 5 mL of normal saline in patients weighing ≥ 10 kg, and withdrawal of at least 1 mL of blood or fluid and infusion of 3 mL of normal saline in patients weighing \< 10 kg.

Time frame:
Up to 7 days post-treatment
Reported as:
Number · percentage of participants
Percentage of Patients Who Had Cumulative Restoration Rates Restoration Rates of CVC Function at Any Time During the Study and Who Maintained Catheter Patency the Next Time the Catheter Was Assessed, up to 7 Days Following the Last Dose of Tenecteplase
percentage of participantsTenecteplase
Percentage of Patients Who Had Cumulative Restoration Rates Restoration Rates of CVC Function at Any Time During the Study and Who Maintained Catheter Patency the Next Time the Catheter Was Assessed, up to 7 Days Following the Last Dose of Tenecteplase81.0 (74.5 to 87.6)

Adverse events

Collected over The period during which SAEs and non-serious AEs were recorded began at the initiation of study treatment and ended at the follow-up visit 48-96 hours after treatment or at subject discontinuation from the study, whichever was earlier.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tenecteplase—6/246 (2.4%)26/246 (10.6%)
Most frequent serious events
Most frequent serious events
EventTenecteplase
PyrexiaGeneral disorders2/246
HypersensitivityImmune system disorders1/246
Catheter Related InfectionInfections and infestations1/246
Device MalfunctionInjury, poisoning and procedural complications1/246
DehydrationMetabolism and nutrition disorders1/246
Most frequent other events
Showing 10 of 27
Most frequent other events
EventTenecteplase
PyrexiaGeneral disorders4/246
NeutropeniaBlood and lymphatic system disorders3/246
NauseaGastrointestinal disorders2/246
Febrile NeutropeniaBlood and lymphatic system disorders1/246
ConjunctivitisEye disorders1/246
Eye DischargeEye disorders1/246
Abdominal DistensionGastrointestinal disorders1/246
Abdominal PainGastrointestinal disorders1/246
ConstipationGastrointestinal disorders1/246
DiarrhoeaGastrointestinal disorders1/246

Baseline characteristics

Age Continuous
Age Continuous(Years)Tenecteplase
Mean43.6 ± 26.4
Age, Customized
Age, Customized(participants)Tenecteplase
< 2 years10
≥ 2 to < 17 years62
≥ 17 to < 65 years111
≥ 65 years63
Sex: Female, Male
Sex: Female, Male(Participants)Tenecteplase
Female155
Male91
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006 and a primary completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years 10 months after primary completion. A results delay was requested in Jun 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2006
First posted
Nov 6, 2006
Start
Dec 2006
Primary completionActual
Jun 2008
Results delay requested
Jun 10, 2009
Results first posted
Apr 27, 2011
Last update
Apr 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00396318
Lead sponsor
Genentech, Inc.
First posted
Nov 6, 2006
Start date
Dec 2006
Primary completion
Jun 2008
Results posted
Apr 27, 2011
Last update
Apr 27, 2011

Study contacts

Barbara Gillespie, M.D., FASN
study director · Quintiles, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion